RecruitingNot ApplicableNCT06400927

Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure

Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure: A Randomized Controlled Pilot Study: ASSIST-HF SIRIO

Sponsor

East and North Hertfordshire NHS Trust

Enrollment

60 participants

Start Date

May 7, 2024

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

The aim of this pilot randomized study is to examine whether integrating the SIRIO-HF virtual assistant (VA) into the outpatient management of participants recently discharged from hospital with a new diagnosis of heart failure (HF), may reduce the need for regular medical assessment and the healthcare burden, reduce variability in healthcare, and meet with participant satisfaction, without compromising participant safety and overall care quality.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether an AI-powered virtual assistant can safely help heart failure patients monitor their condition and follow their care plan after being discharged from the hospital. Researchers want to see if the AI tool can catch early warning signs and reduce readmissions. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with heart failure - Your heart failure symptoms are classified as mild to moderate (NYHA class II or III) at discharge **You may NOT be eligible if...** - You have a prior history of heart failure - You have severe other medical conditions that might interfere with the study - Your breathlessness is caused by another condition like COPD rather than heart failure - You have dementia or significant cognitive impairment - You are currently in another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.